Literature DB >> 19064725

BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.

Amanda Nordigården1, Maria Kraft, Pernilla Eliasson, Verena Labi, Eric W-F Lam, Andreas Villunger, Jan-Ingvar Jönsson.   

Abstract

Constitutively activating internal tandem duplications (ITD) of FLT3 (FMS-like tyrosine kinase 3) are the most common mutations in acute myeloid leukemia (AML) and correlate with poor prognosis. Receptor tyrosine kinase inhibitors targeting FLT3 have developed as attractive treatment options. Because relapses occur after initial responses, identification of FLT3-ITD-mediated signaling events are important to facilitate novel therapeutic interventions. Here, we have determined the growth-inhibitory and proapoptotic mechanisms of 2 small molecule inhibitors of FLT3, AG1295 or PKC412, in hematopoietic progenitor cells, human leukemic cell lines, and primary AML cells expressing FLT3-ITD. Inactivation of the PI3-kinase pathway, but not of Ras-mitogen-activated protein (MAP) kinase signaling, was essential to elicit cytotoxic responses. Both compounds induced up-regulation of proapoptotic BH3-only proteins Bim and Puma, and subsequent cell death. However, only silencing of Bim, or its direct transcriptional activator FOXO3a, abrogated apoptosis efficiently. Similar findings were made in bone marrow cells from gene-targeted mice lacking Bim and/or Puma infected with FLT3-ITD and treated with inhibitor, where loss of Puma only provided transient protection from apoptosis, but loss of Bim preserved clonal survival upon FLT3-ITD inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19064725      PMCID: PMC3272395          DOI: 10.1182/blood-2008-07-167023

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

2.  A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.

Authors:  T Meyer; U Regenass; D Fabbro; E Alteri; J Rösel; M Müller; G Caravatti; A Matter
Journal:  Int J Cancer       Date:  1989-05-15       Impact factor: 7.396

3.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

4.  Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

Authors:  Jennifer J Clark; Jan Cools; David P Curley; Jin-Chen Yu; Nathalie A Lokker; Neill A Giese; D Gary Gilliland
Journal:  Blood       Date:  2004-07-15       Impact factor: 22.113

5.  FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3.

Authors:  Maria Jönsson; Maria Engström; Jan-Ingvar Jönsson
Journal:  Biochem Biophys Res Commun       Date:  2004-06-11       Impact factor: 3.575

6.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Authors:  Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo L Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

7.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

Authors:  Richard M Stone; Daniel J DeAngelo; Virginia Klimek; Ilene Galinsky; Eli Estey; Stephen D Nimer; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A Fox; Donna Neuberg; Jennifer Clark; D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

8.  Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.

Authors:  Ryoko Kuribara; Hiroaki Honda; Hirotaka Matsui; Tetsuharu Shinjyo; Takeshi Inukai; Kanji Sugita; Shinpei Nakazawa; Hisamaru Hirai; Keiya Ozawa; Toshiya Inaba
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

9.  In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

Authors:  Mark Levis; Rosalyn Pham; B Douglas Smith; Donald Small
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

10.  Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

Authors:  Kevin W H Yee; Marcus Schittenhelm; Anne-Marie O'Farrell; Ajia R Town; Laura McGreevey; Troy Bainbridge; Julie M Cherrington; Michael C Heinrich
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  16 in total

1.  An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

Authors:  Sayer Al-Harbi; Brian T Hill; Suparna Mazumder; Kamini Singh; Jennifer Devecchio; Gaurav Choudhary; Lisa A Rybicki; Matt Kalaycio; Jaroslaw P Maciejewski; Janet A Houghton; Alexandru Almasan
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

2.  EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.

Authors:  Sharmila Shankar; Luke Marsh; Rakesh K Srivastava
Journal:  Mol Cell Biochem       Date:  2012-09-13       Impact factor: 3.396

3.  BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Authors:  William E Pierceall; Steven M Kornblau; Nicole E Carlson; Xuelin Huang; Noel Blake; Ryan Lena; Michael Elashoff; Marina Konopleva; Michael H Cardone; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

4.  Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim.

Authors:  Jieru Meng; Bingliang Fang; Yong Liao; Christine M Chresta; Paul D Smith; Jack A Roth
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

5.  Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.

Authors:  Jie Chen; Ana R Gomes; Lara J Monteiro; San Yu Wong; Lai Han Wu; Ting-Ting Ng; Christina T Karadedou; Julie Millour; Ying-Chi Ip; Yuen Nei Cheung; Andrew Sunters; Kelvin Y K Chan; Eric W-F Lam; Ui-Soon Khoo
Journal:  PLoS One       Date:  2010-08-20       Impact factor: 3.240

6.  Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment.

Authors:  Amandine Savry; Manon Carre; Raphael Berges; Amandine Rovini; Isabelle Pobel; Christine Chacon; Diane Braguer; Véronique Bourgarel-Rey
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

Review 7.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

8.  The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.

Authors:  Jenny E Hernandez-Davies; Joan P Zape; Elliot M Landaw; Xiaolin Tan; Ajia Presnell; Diana Griffith; Michael C Heinrich; Keith B Glaser; Kathleen M Sakamoto
Journal:  Mol Cancer Ther       Date:  2011-04-06       Impact factor: 6.261

9.  FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.

Authors:  Ruiqi Zhu; Li Li; Bao Nguyen; Jaesung Seo; Min Wu; Tessa Seale; Mark Levis; Amy Duffield; Yu Hu; Donald Small
Journal:  Signal Transduct Target Ther       Date:  2021-05-24

10.  Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.

Authors:  Joëlle Rubert; Zhiyan Qian; Rita Andraos; Daniel A Guthy; Thomas Radimerski
Journal:  BMC Cancer       Date:  2011-01-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.